February 17, 2021 04:20 PM ESTUpdated February 19, 08:11 AM
Financing

Spy­Biotech cash­es in on Serum In­sti­tute deal, net­ting $32.5M round for its 'su­per­glue' VLP vac­cine tech

Max Gelman

Senior Editor

Rough­ly five months af­ter part­ner­ing with the Serum In­sti­tute of In­dia to de­vel­op Covid-19 vac­cines, Spy­Biotech is ready for its next big thing.

The British …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

For CDC, Trump picks Dave Wel­don, a for­mer con­gress­man who pushed for vac­cine in­jury claims

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

A service from the Financial Times